Literature DB >> 16816952

Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.

G Tonini, C Bizzarri, R Bonfanti, M Vanelli, F Cerutti, E Faleschini, F Meschi, F Prisco, E Ciacco, M Cappa, C Torelli, V Cauvin, S Tumini, D Iafusco, F Barbetti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16816952     DOI： 10.1007/s00125-006-0329-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  10 in total

1.  High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation.

Authors:  Ethel Codner; Sarah Flanagan; Sian Ellard; Hernán García; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

2.  Relapsing diabetes can result from moderately activating mutations in KCNJ11.

Authors:  Anna L Gloyn; Frank Reimann; Christophe Girard; Emma L Edghill; Peter Proks; Ewan R Pearson; I Karen Temple; Deborah J G Mackay; Julian P H Shield; Debra Freedenberg; Kathryn Noyes; Sian Ellard; Frances M Ashcroft; Fiona M Gribble; Andrew T Hattersley
Journal:  Hum Mol Genet       Date:  2005-02-17       Impact factor: 6.150

3.  The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation.

Authors:  T Klupa; E L Edghill; J Nazim; J Sieradzki; S Ellard; A T Hattersley; M T Malecki
Journal:  Diabetologia       Date:  2005-04-19       Impact factor: 10.122

Review 4.  Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy.

Authors:  Andrew T Hattersley; Frances M Ashcroft
Journal:  Diabetes       Date:  2005-09       Impact factor: 9.461

5.  KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes.

Authors:  Ornella Massa; Dario Iafusco; Elena D'Amato; Anna L Gloyn; Andrew T Hattersley; Bruno Pasquino; Giorgio Tonini; Francesco Dammacco; Giorgio Zanette; Franco Meschi; Ottavia Porzio; Gianfranco Bottazzo; Antonino Crinó; Renata Lorini; Franco Cerutti; Maurizio Vanelli; Fabrizio Barbetti
Journal:  Hum Mutat       Date:  2005-01       Impact factor: 4.878

6.  Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.

Authors:  Amnon Zung; Benjamin Glaser; Revital Nimri; Zvi Zadik
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

7.  ATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes: implications for pharmacogenomic therapy.

Authors:  Joseph C Koster; Maria S Remedi; Crystal Dao; Colin G Nichols
Journal:  Diabetes       Date:  2005-09       Impact factor: 9.461

8.  Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy.

Authors:  Jørn V Sagen; Helge Raeder; Eba Hathout; Naim Shehadeh; Kolbeinn Gudmundsson; Halvor Baevre; Dianne Abuelo; Chanika Phornphutkul; Janne Molnes; Graeme I Bell; Anna L Gloyn; Andrew T Hattersley; Anders Molven; Oddmund Søvik; Pål R Njølstad
Journal:  Diabetes       Date:  2004-10       Impact factor: 9.461

9.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.

Authors:  Anna L Gloyn; Ewan R Pearson; Jennifer F Antcliff; Peter Proks; G Jan Bruining; Annabelle S Slingerland; Neville Howard; Shubha Srinivasan; José M C L Silva; Janne Molnes; Emma L Edghill; Timothy M Frayling; I Karen Temple; Deborah Mackay; Julian P H Shield; Zdenek Sumnik; Adrian van Rhijn; Jerry K H Wales; Penelope Clark; Shaun Gorman; Javier Aisenberg; Sian Ellard; Pål R Njølstad; Frances M Ashcroft; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

10.  Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation.

Authors:  C Colombo; M Delvecchio; C Zecchino; M F Faienza; L Cavallo; F Barbetti
Journal:  Diabetologia       Date:  2005-10-05       Impact factor: 10.122
  10 in total
  23 in total

1.  No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes.

Authors:  D Iafusco; C Bizzarri; F Cadario; R Pesavento; G Tonini; S Tumini; V Cauvin; C Colombo; R Bonfanti; F Barbetti
Journal:  Diabetologia       Date:  2011-08-07       Impact factor: 10.122

Review 2.  Neonatal diabetes mellitus: a model for personalized medicine.

Authors:  Siri Atma W Greeley; Susan E Tucker; Rochelle N Naylor; Graeme I Bell; Louis H Philipson
Journal:  Trends Endocrinol Metab       Date:  2010-04-29       Impact factor: 12.015

Review 3.  Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations.

Authors:  Lisa R Letourneau; Siri Atma W Greeley
Journal:  Curr Diab Rep       Date:  2019-06-27       Impact factor: 4.810

4.  Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with the KCNJ11/S225T, del226-232 mutation.

Authors:  Domenica Battaglia; Yu-Wen Lin; Claudia Brogna; Antonino Crinò; Valeria Grasso; Alessia F Mozzi; Lucia Russo; Sabrina Spera; Carlo Colombo; Stefano Ricci; Colin G Nichols; Eugenio Mercuri; Fabrizio Barbetti
Journal:  Pediatr Diabetes       Date:  2012-06-14       Impact factor: 4.866

5.  Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus.

Authors:  Carlo Colombo; Ottavia Porzio; Ming Liu; Ornella Massa; Mario Vasta; Silvana Salardi; Luciano Beccaria; Carla Monciotti; Sonia Toni; Oluf Pedersen; Torben Hansen; Luca Federici; Roberta Pesavento; Francesco Cadario; Giorgio Federici; Paolo Ghirri; Peter Arvan; Dario Iafusco; Fabrizio Barbetti
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

6.  Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.

Authors:  Maria Al-Mahdi; Angham Al Mutair; Mohammed Al Balwi; Khalid Hussain
Journal:  Ann Saudi Med       Date:  2010 Mar-Apr       Impact factor: 1.526

Review 7.  K(ATP) channelopathies in the pancreas.

Authors:  Maria S Remedi; Joseph C Koster
Journal:  Pflugers Arch       Date:  2009-11-18       Impact factor: 3.657

8.  The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.

Authors:  Joseph C Koster; Francesco Cadario; Cinzia Peruzzi; Carlo Colombo; Colin G Nichols; Fabrizio Barbetti
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

9.  Transition from insulin to sulfonylurea in a child with diabetes due to a mutation in KCNJ11 encoding Kir6.2--initial and long-term response to sulfonylurea therapy.

Authors:  Verena M Wagner; Britta Kremke; Olaf Hiort; Sarah E Flanagan; Ewan R Pearson
Journal:  Eur J Pediatr       Date:  2008-06-12       Impact factor: 3.183

Review 10.  Neonatal diabetes mellitus.

Authors:  Lydia Aguilar-Bryan; Joseph Bryan
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.